Is recro Pharma efficiently growing its dividend?
Recro Pharma does not have a long track record of dividend growth. In the past three months, Recro Pharma insiders have sold 2,451.69% more of their company's stock than they have bought. Specifically, they have bought $8,593.00 in company stock and sold $219,267.00 in company stock.
Should you buy recro Pharma (RPC) stock?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Recro Pharma stock.
What is the PE (price earnings) ratio of recro Pharma?
The P/E ratio of Recro Pharma is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Is Recro Pharma a buy right now?
Where can I buy reph shares?
Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is Recro Pharma's consensus rating?
According to the issued ratings of 1 analysts in the last year, the consensus rating for Recro Pharma stock is Buy based on the current 1 buy ratin...
Do Wall Street analysts like Recro Pharma more than its competitors?
Analysts like Recro Pharma stock more than the stock of other Medical companies. The consensus rating score for Recro Pharma is 3.00 while the aver...
Do MarketBeat users like Recro Pharma more than its competitors?
MarketBeat users like Recro Pharma stock less than the stock of other Medical companies. 66.22% of MarketBeat users gave Recro Pharma an outperform...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Recro Reports Inducement Grants For New Staff
Latest Appointment Continues Build-Out of Leadership Team for San Diego OperationsSAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc.
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc.
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc.
Recro to Present at Stephens Annual Investment Conference
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
5 Penny Stocks Insiders Are Buying
Fireside Chat Webcast AvailableSAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc.
Recro Reports Third Quarter 2021 Financial Results
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks.
Recro Pharma (NASDAQ:REPH) Price Target and Consensus Rating
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Recro Pharma (NASDAQ:REPH) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Recently Viewed Tickers
According to the issued ratings of 1 analysts in the last year, the consensus rating for Recro Pharma stock is Buy based on the current 1 buy rating for REPHthe . Learn more on REPH's analyst rating history
Recro Pharma Inc
Visit a quote page and your recently viewed tickers will be displayed here.
